Literature DB >> 19366810

p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases.

Takehiko Yokobori1, Koshi Mimori, Masaaki Iwatsuki, Hideshi Ishii, Ichiro Onoyama, Takeo Fukagawa, Hiroyuki Kuwano, Keiichi I Nakayama, Masaki Mori.   

Abstract

A molecular target associated with the progression of gastric cancer has not yet been uncovered. FBXW7 is a tumor suppressor gene transcriptionally controlled by p53 that plays a role in the regulation of cell cycle exit and reentry via c-Myc degradation. Few studies have addressed the clinical significance of FBXW7 expression in gastric cancer. Therefore, we examined FBXW7 mRNA expression to determine its clinicopathologic significance in 100 cases of gastric cancer. Low expression levels of FBXW7 in primary gastric cancer contributed to malignant potential, such as lymph node metastasis (P = 0.0012), tumor size (P = 0.0003), and poor prognosis (P = 0.018). In comparison with 52 cases of gastric cancer without the p53 mutation, 29 cases with the mutation exhibited lower expression levels of FBXW7 (P = 0.0034), revealing a significant relationship between p53 mutation and FBXW7 expression. Furthermore, we found that gastric cancer patients who had low FBXW7 expression levels and p53 mutation had a distinctively poor prognosis in comparison with other subgroups (P = 0.0033). In conclusion, we showed a role for p53 in the transcriptional regulation of FBXW7 expression in clinical gastric cancer cases and showed that disruption of both p53 and FBXW7 contributes to poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19366810     DOI: 10.1158/0008-5472.CAN-08-2846

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  69 in total

1.  miR-223/FBW7 axis regulates doxorubicin sensitivity through epithelial mesenchymal transition in non-small cell lung cancer.

Authors:  Renyuan Li; Shengjun Wu; Xin Chen; Hongfei Xu; Peng Teng; Weidong Li
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

2.  MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4.

Authors:  Jinhai Li; Yuanyuan Guo; Xiaodi Liang; Ming Sun; Guoliang Wang; Wei De; Wenxi Wu
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-22       Impact factor: 4.553

Review 3.  The two faces of FBW7 in cancer drug resistance.

Authors:  Zhiwei Wang; Hidefumi Fukushima; Daming Gao; Hiroyuki Inuzuka; Lixin Wan; Alan W Lau; Pengda Liu; Wenyi Wei
Journal:  Bioessays       Date:  2011-08-30       Impact factor: 4.345

Review 4.  Role of E3 ubiquitin ligases in gastric cancer.

Authors:  Ya-Chao Hou; Jing-Yu Deng
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

5.  Oncogenic mutations in the FBXW7 gene of adult T-cell leukemia patients.

Authors:  Chien-Hung Yeh; Marcia Bellon; Joanna Pancewicz-Wojtkiewicz; Christophe Nicot
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-31       Impact factor: 11.205

6.  Poor survival with wild-type TP53 ovarian cancer?

Authors:  Kwong-Kwok Wong; Daisy I Izaguirre; Suet-Yan Kwan; Erin R King; Michael T Deavers; Anil K Sood; Samuel C Mok; David M Gershenson
Journal:  Gynecol Oncol       Date:  2013-06-22       Impact factor: 5.482

Review 7.  The role of cullin proteins in gastric cancer.

Authors:  Peng Chen; Guo-Dong Yao
Journal:  Tumour Biol       Date:  2015-10-15

8.  Tumor suppressor Fbxw7 antagonizes WNT signaling by targeting β-catenin for degradation in pancreatic cancer.

Authors:  Jian-Xin Jiang; Cheng-Yi Sun; She Tian; Chao Yu; Mei-Yuan Chen; Hao Zhang
Journal:  Tumour Biol       Date:  2016-08-03

9.  Promotional effect of microRNA-194 on breast cancer cells via targeting F-box/WD repeat-containing protein 7.

Authors:  Yaomin Chen; Haiyan Wei; Yu Liu; Shusen Zheng
Journal:  Oncol Lett       Date:  2018-01-23       Impact factor: 2.967

Review 10.  Roles of F-box proteins in cancer.

Authors:  Zhiwei Wang; Pengda Liu; Hiroyuki Inuzuka; Wenyi Wei
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.